Aspen Pharmacare Holdings Yönetim

Yönetim kriter kontrolleri 4/4

Aspen Pharmacare Holdings CEO'su Stephen Saad, Jan2000 tarihinde atandı, in görev süresi 24.83 yıldır. in toplam yıllık tazminatı ZAR 27.30M olup, şirket hissesi ve opsiyonları dahil olmak üzere 35.2% maaş ve 64.8% ikramiyelerden oluşmaktadır. şirketin hisselerinin 11.82% ine doğrudan sahiptir ve bu hisseler € 470.10M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 7.7 yıl ve 5.6 yıldır.

Anahtar bilgiler

Stephen Saad

İcra Kurulu Başkanı

R27.3m

Toplam tazminat

CEO maaş yüzdesi	35.2%
CEO görev süresi	24.8yrs
CEO sahipliği	11.8%
Yönetim ortalama görev süresi	7.7yrs
Yönetim Kurulu ortalama görev süresi	5.6yrs

Son yönetim güncellemeleri

Recent updates

CEO Tazminat Analizi

Stephen Saad'un ücretlendirmesi Aspen Pharmacare Holdings'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Jun 30 2024	R27m	R10m	R4b
Mar 31 2024	n/a	n/a	R5b
Dec 31 2023	n/a	n/a	R5b
Sep 30 2023	n/a	n/a	R5b
Jun 30 2023	R24m	R9m	R5b
Mar 31 2023	n/a	n/a	R6b
Dec 31 2022	n/a	n/a	R6b
Sep 30 2022	n/a	n/a	R6b
Jun 30 2022	R23m	R9m	R6b
Mar 31 2022	n/a	n/a	R6b
Dec 31 2021	n/a	n/a	R6b
Sep 30 2021	n/a	n/a	R5b
Jun 30 2021	R24m	R8m	R5b
Mar 31 2021	n/a	n/a	R4b
Dec 31 2020	n/a	n/a	R4b
Sep 30 2020	n/a	n/a	R4b
Jun 30 2020	R23m	R8m	R3b
Mar 31 2020	n/a	n/a	R3b
Dec 31 2019	n/a	n/a	R870m
Sep 30 2019	n/a	n/a	R1b
Jun 30 2019	R14m	R8m	R2b
Mar 31 2019	n/a	n/a	R3b
Dec 31 2018	n/a	n/a	R5b
Sep 30 2018	n/a	n/a	R5b
Jun 30 2018	R17m	R7m	R6b

Tazminat ve Piyasa: Stephen 'ın toplam tazminatı ($USD 1.50M ) German pazarındaki benzer büyüklükteki şirketler için ortalamadır ($USD 1.95M ).

Tazminat ve Kazançlar: Stephen 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.

CEO

Stephen Saad (60 yo)

24.8yrs

Görev süresi

R27,303,000

Tazminat

Mr. Stephen Bradley Saad, BCom, CA(SA), serves as the Group Chief Executive Officer of Aspen Pharmacare Canada Inc. Mr. Stephen has been the Group Chief Executive Officer of Aspen Pharmacare Holdings Limit...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Stephen Saad	Group CEO & Executive Director	24.8yrs	R27.30m	11.82% € 468.3m
Sean Capazorio	Group CFO & Executive Director	25.8yrs	R16.66m	Veri yok
Lorraine Hill	Group Chief Operations Officer & Responsible Pharmacist	11yrs	R17.18m	Veri yok
Michael Attridge	Group Chief Advisor	2.8yrs	R11.14m	4.32% € 171.3m
Reginald Haman	Group Chief Corporate Services Officer & Executive Director	less than a year	R13.79m	Veri yok
Zizipho Mmango	Group Chief Strategic Development Officer	4.5yrs	R12.81m	Veri yok
Sibongakonke Nkosi	Investor Relations Manager	no data	Veri yok	Veri yok
Raeesa Khan	Group Company Secretary & Chief of Staff	less than a year	Veri yok	Veri yok
Trevor Ziman	Regional Chief Executive Officer of Asia Pacific	10.8yrs	Veri yok	Veri yok
Samer Kassem	Chief Executive Officer of Aspen Global Incorporated	7.7yrs	Veri yok	Veri yok
Luresha Chetty	Corporate Affairs & Investor Relations Executive	no data	Veri yok	Veri yok

7.7yrs

Ortalama Görev Süresi

54.5yo

Ortalama Yaş

Deneyimli Yönetim: LDZA 'un yönetim ekibi deneyimli ve deneyimlidir ( 7.7 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Stephen Saad	Group CEO & Executive Director	25.8yrs	R27.30m	11.82% € 468.3m
Sean Capazorio	Group CFO & Executive Director	2.8yrs	R16.66m	Veri yok
Reginald Haman	Group Chief Corporate Services Officer & Executive Director	less than a year	R13.79m	Veri yok
Ben Kruger	Lead Independent Non-Executive Director	5.6yrs	R1.27m	Veri yok
Christopher Mortimer	Non-Executive Director	25.8yrs	R551.00k	Veri yok
Kuseni Dlamini	Independent Non-Executive Chairman	12.6yrs	R1.49m	Veri yok
Yvonne Muthien	Independent Non-Executive Director	2.9yrs	R1.08m	Veri yok
David Redfern	Non-Executive Director	9.8yrs	R427.00k	Veri yok
Linda de Beer	Independent Non-Executive Director	6.3yrs	R1.14m	Veri yok
Neo Dongwana	Independent Non-Executive Director	less than a year	R183.00k	Veri yok
Themba Mkhwanazi	Independent Non-Executive Director	5.6yrs	R432.00k	Veri yok

5.6yrs

Ortalama Görev Süresi

57yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: LDZA 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 5.6 yıldır).

Aspen Pharmacare Holdings Yönetim

Yönetim kriter kontrolleri 4/4

Anahtar bilgiler

Son yönetim güncellemeleri

Aspen Pharmacare Holdings Limited, Annual General Meeting, Dec 05, 2024

Aspen Pharmacare Holdings Limited Announces Changes to its Board

Aspen Pharmacare Holdings Limited Announces Changes to the Board Committees

Aspen Pharmacare Holdings Limited Announces Demise of Riaan Verster, Company Secretary

Sindi Zilwa to Step Down as Member of Audit & Risk Committee of Aspen Pharmacare Holdings Limited with Effect from 15 October 2020

Recent updates

Full year 2024 earnings released: EPS: R9.91 (vs R11.77 in FY 2023)

Investor sentiment deteriorates as stock falls 15%

Full year 2024 earnings released: EPS: R9.91 (vs R11.77 in FY 2023)

Dividend of R3.59 announced

Aspen Pharmacare Holdings Limited Declares Gross Dividend, Payable on 23 September 2024

Aspen Pharmacare Holdings Limited, Annual General Meeting, Dec 05, 2024

Aspen Pharmacare Holdings Limited to Report First Half, 2024 Results on Mar 04, 2024

Aspen Pharmacare Holdings Limited Announces Changes to its Board

Upcoming dividend of R3.42 per share at 2.0% yield

Full year 2023 earnings released: EPS: R11.77 (vs R14.32 in FY 2022)

Aspen Pharmacare Holdings Limited Declares Gross Dividend, Payable on 26 September 2023

Aspen Pharmacare Holdings Limited Announces Changes to the Board Committees

Investor sentiment improves as stock rises 17%

First half 2023 earnings released: EPS: R6.02 (vs R7.36 in 1H 2022)

Aspen Pharmacare Holdings Limited Announces Demise of Riaan Verster, Company Secretary

Aspen Pharmacare Holdings Limited to Report Fiscal Year 2023 Results on Aug 30, 2023

Upcoming dividend of R3.26 per share

Full year 2022 earnings released: EPS: R14.32 (vs R10.51 in FY 2021)

First half 2022 earnings: Revenues and EPS in line with analyst expectations

Investor sentiment improved over the past week

NTC and Aspen Announce SAHPRA Positive Outcome for the Fixed Dose Combination of Levofloxacin and Dexamethasone Multidose Eye Drops

Full year 2021 earnings released: EPS R10.51 (vs R7.40 in FY 2020)

Investor sentiment improved over the past week

Upcoming dividend of R2.62 per share

Suitors Offer to Buy Aspen's Parts of Business

Full year 2021 earnings released: EPS R10.51 (vs R10.10 in FY 2020)

Director Sindiswa Zilwa has joined 5th company board

Director Sindiswa Zilwa has joined 5th company board

Director Sindiswa Zilwa has joined 5th company board

Director Sindiswa Zilwa has joined 5th company board

Director Sindiswa Zilwa has joined 5th company board

First half 2021 earnings released: EPS R4.99 (vs R4.11 in 1H 2020)

New 90-day high: €8.50

New 90-day high: €7.20

New 90-day high: €7.10

Market bids up stock over the past week

Full year 2020 earnings released: EPS R10.10

Revenue misses expectations

New 90-day low: €5.65

Groupe Lactalis S.A. completed the acquisition of global nutritionals business from Aspen Pharmacare Holdings Limited (JSE:APN).

New 90-day low: €6.15

Sindi Zilwa to Step Down as Member of Audit & Risk Committee of Aspen Pharmacare Holdings Limited with Effect from 15 October 2020

Full year earnings released - EPS €10.10

New 90-day low - €6.25

CEO Tazminat Analizi

CEO

Görev süresi

Tazminat

Liderlik Ekibi

Ortalama Görev Süresi

Ortalama Yaş

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi

Ortalama Yaş